Cancer is characterized by the presence of mutated alleles in DNA, leading to the formation of tumors. A delayed diagnosis of this condition can result in fatal outcomes, making it a significant global cause of mortality. WHO has emphasized that early detection could significantly increase the chances of successful treatment and recovery. Traditional cancer diagnosis relies on invasive tissue biopsies, which pose risks to both patient’s and healthcare professionals due to the use of formaldehyde, a known carcinogenic agent, for specimen preservation. In recent times, liquid biopsies have emerged as a promising alternative, particularly for the analysis of circulating tumor DNA (ctDNA), a fraction of which originates from tumor cells and circulates in the bloodstream. However, conventional molecular genetic tests for ctDNA analysis are often costly and time-consuming. Advancements in technology and the field of nanoscience offer the potential to develop cost-effective, rapid, highly sensitive, and selective diagnostic tools. Among these, biosensors stand out as a promising option. In this article, we delve into the quantification of ctDNA in plasma, discuss amplification techniques for ctDNA, and explore the development of electrochemical-based biosensors tailored for ctDNA detection. Finally, we highlight recent studies and innovations in the field of ctDNA detection.
Liquid biopsies Circulating tumor DNA ctDNA Amplification techniques Biosensors Electrochemical detection
Primary Language | English |
---|---|
Subjects | Biomedical Engineering (Other), Bioengineering (Other) |
Journal Section | Research Article |
Authors | |
Publication Date | June 21, 2024 |
Submission Date | October 16, 2023 |
Acceptance Date | January 8, 2024 |
Published in Issue | Year 2024 |
Manas Journal of Engineering